The complex interplay between cholesterol and prostate malignancy.
The complex interplay between cholesterol and prostate malignancy.
复制标题
DOI：
10.1016/j.ucl.2011.04.001
复制
发表时间：
2011-08
影响因子：
2.4
通讯作者：
Freeman, Michael R.
中科院分区：
文献类型：
--
作者：
Solomon, Keith R.;Freeman, Michael R.
关于胆固醇和前列腺疾病的作用的研究已经进行了很多年，但是我们对胆固醇和前列腺疾病的机制和转化的理解仍然很差。最近的证据表明，降胆固醇药物可以降低侵袭性前列腺癌的风险，然而，多年来在这一领域进行的研究反映了许多争议和不确定性。在这里，我们探讨了循环胆固醇和前列腺癌之间的关系的整个文献，考虑和旧的和新的研究的批评。我们考虑了为什么低胆固醇与晚期前列腺癌风险的增加和降低有关，并解释了为什么这两种观察结果可能是正确的。我们讨论了他汀类药物与观察性研究的随机安慰剂对照试验的相互矛盾的结果，并证明了普伐他汀在随机试验中的优势描绘了他汀类药物作用的扭曲观点。最后，我们讨论了新的数据表明，胆固醇在前列腺癌进展中的作用的一个关键方面是通过其在瘤内类固醇生成的作用。通过解决这些问题，数据有力地表明高胆固醇血症是前列腺癌进展的风险因素，并表明使用降胆固醇疗法改变病程的临床机会。
Research into the topic of the role of cholesterol and prostate disease has been ongoing for many years, however our mechanistic and translational understanding is still poor. Recent evidence indicates that cholesterol lowering drugs reduce the risk of aggressive prostate cancer, however the studies in this area, performed over many years, reflect much controversy and uncertainty. Here we explore the entire literature on the relationship between circulating cholesterol and prostate cancer, with consideration and criticism of the older as well as the newer studies. We consider why low cholesterol is associated with both increased and decreased risk of advanced prostate cancer, and explain why both observations are probably correct. We discuss the conflicting results of randomized placebo-controlled trials of statin drugs vs. observational studies and demonstrate that a predominance of pravastatin in the randomized trials paints a distorted view of statin effects. Lastly, we discuss new data suggesting that a critical aspect of the role of cholesterol in prostate cancer progression is through its role in intratumoral steroidogenesis. With these points addressed, the data strongly point to hypercholesterolemia as a risk factor for prostate cancer progression and suggest clinical opportunities for the use of cholesterol lowering therapies to alter disease course.
登录
查看更多内容
影响因子：
2.3
作者：
Batty, G. David;Kivimaeki, Mika;Clarke, Robert;Smith, George Davey;Shipley, Martin J.
通讯作者：
Shipley, Martin J.
影响因子：
13.2
作者：
Chonchol, Michel;Cook, Thomas;Lindenfeld, JoAnn
通讯作者：
Lindenfeld, JoAnn
影响因子：
5
作者：
CAMBIEN, F;DUCIMETIERE, P;RICHARD, J
通讯作者：
RICHARD, J
影响因子：
12.8
作者：
An, Sojin;Jang, Young-Soon;Jeong, Tae-Sook
通讯作者：
Jeong, Tae-Sook
DOI：
10.1200/jco.2008.20.0642
发表时间：
2009-08-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Attard G;Reid AH;A'Hern R;Parker C;Oommen NB;Folkerd E;Messiou C;Molife LR;Maier G;Thompson E;Olmos D;Sinha R;Lee G;Dowsett M;Kaye SB;Dearnaley D;Kheoh T;Molina A;de Bono JS
通讯作者：
de Bono JS